FDA grants emergency use authorization to Moderna's COVID-19 mRNA vaccine

Moderna/Respiratory vaccines

The FDA authorized Moderna's mRNA-1273 COVID-19 vaccine for emergency use on December 18, 2020, the second vaccine cleared after Pfizer-BioNTech. The vaccine was co-developed with the National Institutes of Health; in the 30,000-person Phase 3 trial it was 94.1% effective against symptomatic COVID-19.

• EUA issued December 18, 2020, for adults 18 years and older.
• Second vaccine cleared after Pfizer-BioNTech, which received authorization the previous week.
• Co-developed with NIH; Phase 3 efficacy of 94.1% against symptomatic COVID-19.